Home > Publications database > Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. > print

001     134799
005     20240229105041.0
024 7 _ |a 10.1007/s00259-018-3965-8
|2 doi
024 7 _ |a pmid:29497802
|2 pmid
024 7 _ |a 0340-6997
|2 ISSN
024 7 _ |a 1432-105X
|2 ISSN
024 7 _ |a 1619-7070
|2 ISSN
024 7 _ |a 1619-7089
|2 ISSN
024 7 _ |a altmetric:33890036
|2 altmetric
037 _ _ |a DKFZ-2018-00592
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Afshar-Oromieh, Ali
|0 0000-0002-4492-4243
|b 0
245 _ _ |a Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT.
260 _ _ |a Heidelberg [u.a.]
|c 2018
|b Springer-Verl.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1565682851_349
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Since the introduction of 68Ga-PSMA-11 PET/CT for imaging prostate cancer (PC) we have frequently observed mediastinal lymph nodes (LN) showing tracer uptake despite being classified as benign. The aim of this evaluation was to further analyze such LN.Two patient groups with biphasic 68Ga-PSMA-11 PET/CT at 1 h and 3 h p.i. were included in this retrospective evaluation. Group A (n = 38) included patients without LN metastases, and group B (n = 43) patients with LN metastases of PC. SUV of mediastinal/paraaortal LN of group A (n = 100) were compared to SUV of LN metastases of group B (n = 91). Additionally, 22 randomly selected mediastinal and paraaortal LN of patients without PC were immunohistochemically (IHC) analyzed for PSMA expression.In group A, 7/38 patients (18.4%) presented with at least one PSMA-positive mediastinal LN at 1 h p.i. and 3/38 (7.9%) positive LN at 3 h p.i. with a SUVmax of 2.3 ± 0.7 at 1 h p.i. (2.0 ± 0.7 at 3 h p.i.). A total of 11 PSMA-positive mediastinal/paraaortal LN were detected in nine patients considering both imaging timing points. SUVmax of LN-metastases was 12.5 ± 13.2 at 1 h p.i. (15.8 ± 17.0 at 3 h p.i.). SUVmax increased clearly (> 10%) between 1 h and 3 h p.i. in 76.9% of the LN metastases, and decreased significantly in 72.7% of the mediastinal/paraaortal LN. By IHC, PSMA-expression was observed in intranodal vascular endothelia of all investigated LN groups and to differing degrees within germinal centers of 15/22 of them (68.1%). Expression was stronger in mediastinal nodes (p = 0.038) and when follicular hyperplasia was present (p = 0.050).PSMA-positive mediastinal/paraaortal benign LN were visible in a notable proportion of patients. PSMA-positivity on the histopathological level was associated with the activation state of the LN. However, in contrast to LN metastases of PC, they presented with significantly lower uptake, which, in addition, usually decreased over time.
536 _ _ |a 319H - Addenda (POF3-319H)
|0 G:(DE-HGF)POF3-319H
|c POF3-319H
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Sattler, Lars Peter
|b 1
700 1 _ |a Steiger, Katja
|b 2
700 1 _ |a Holland-Letz, Tim
|0 P:(DE-He78)457c042884c901eb0a02c18bb1d30103
|b 3
|u dkfz
700 1 _ |a da Cunha, Marcelo Livorsi
|b 4
700 1 _ |a Mier, Walter
|b 5
700 1 _ |a Neels, Oliver
|0 P:(DE-He78)4f3bf0db0166b782272f523c85369931
|b 6
|u dkfz
700 1 _ |a Kopka, Klaus
|0 P:(DE-He78)9793347ba83f527b81a22ab75af9378a
|b 7
|u dkfz
700 1 _ |a Weichert, Wilko
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Haberkorn, Uwe
|b 9
773 _ _ |a 10.1007/s00259-018-3965-8
|g Vol. 45, no. 7, p. 1179 - 1187
|0 PERI:(DE-600)2098375-X
|n 7
|p 1179 - 1187
|t European journal of nuclear medicine and molecular imaging
|v 45
|y 2018
|x 1619-7089
909 C O |o oai:inrepo02.dkfz.de:134799
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)457c042884c901eb0a02c18bb1d30103
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)4f3bf0db0166b782272f523c85369931
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)9793347ba83f527b81a22ab75af9378a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-319H
|2 G:(DE-HGF)POF3-300
|v Addenda
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NUCL MED MOL I : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NUCL MED MOL I : 2015
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
920 1 _ |0 I:(DE-He78)E030-20160331
|k E030
|l Radiopharmazeutische Chemie
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
920 1 _ |0 I:(DE-He78)L701-20160331
|k L701
|l DKTK München
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)E030-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)L701-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21